Vaccine pharmacotherapy for the treatment of cocaine dependence.
BACKGROUND
Cocaine abuse has no established pharmacotherapy, but active immunotherapy with a cocaine vaccine shows promise as a therapeutic intervention.


METHODS
An open label, fourteen week, dose-escalation study evaluated the safety, immunogenicity, and clinical efficacy of a novel human cocaine vaccine (TA-CD) in eighteen cocaine dependent subjects. Ten subjects (400 microg total dose group) received four-100 microg injections over the course of eight weeks. Subsequently, eight subjects (2000 microg total dose group) received five-400 microg vaccinations over twelve weeks. Intent to treat analysis of thrice weekly urine toxicologies and cocaine antibody titers were compared.


RESULTS
Sixteen of 18 subjects completed the study. There were no serious adverse reactions and the vaccine was well tolerated. The 2000 microg total dose group had a significantly higher mean antibody titer response (2000 units) as compared to the 400 microg total dose group (1000 units) (p = .05). The 2000 microg group was more likely to maintain cocaine free urines than those in the 400 microg group (Z = -3.12, p = .002). Despite relapse in both groups, most reported an attenuation of cocaine's usual euphoric effects at the six month follow-up time points (63% in the 400 microg and 100% in the 2000 microg groups).


CONCLUSIONS
The conjugated cocaine vaccine was well tolerated and cocaine specific antibodies persisted at least six months. The likelihood of using cocaine decreased in subjects who received the more intense vaccination schedule.
Martell
Bridget A
BA
Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. bridget.martell@yale.edu
Mitchell
Ellen
E
Poling
James
J
Gonsai
Kishor
K
Kosten
Thomas R
TR
D000328:Adult; D000906:Antibodies / Q000097:blood; D003042:Cocaine / Q000276:immunology*; D019970:Cocaine-Related Disorders / Q000097:blood / Q000276:immunology* / Q000517:prevention & control* / Q000628:therapy; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D008875:Middle Aged; D014611:Vaccination / Q000379:methods*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use
D000906:Antibodies; D014612:Vaccines; D003042:Cocaine